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Abstract
Lactobacilli, including Lactobacillus rhamnosus, commonly used probiotic bacteria, show the abil-
ity to produce biofilm. Whole lactic acid bacteria, as well as their cell-wall components show strain spe-
cific immunomodulatory properties. Exopolysaccharides (EPSs) are major components of extracellular
polymeric substances and the lactobacilli biofilm matrix. However, in contrast to peptidoglycans or tei-
choic acids, the role of EPS in the modulation of the immune system by lactobacilli is still obscure. Pre-
viously, we have shown that crude EPS (cEPS) isolated from L. rhamnosus KL37C can effectively stim-
ulate production of inflammatory mediators by macrophages in vitro. Moreover, EPS inhibits the production
of anti-collagen specific immunoglobulin G (IgG) in mice. Interestingly, the reduction of anti-collagen
antibodies correlated with the amelioration of collagen-induced arthritis. However, the mechanism of
EPS immunosuppressive activity remains unknown. In this paper we examine the ability of EPS to inhib-
it humoral response to ovalbumin (OVA). The experiments were performed in CBA mice, by immunizing
animals with OVA in the presence of EPS or lipopolysaccharide (LPS). The results showed that EPS inhib-
ited humoral response to OVA. Exopolysaccharide injected simultaneously with the antigen decreased
the production of anti-OVA IgG, IgG1 and IgG2a antibodies. Interestingly, EPS given together with LPS
diminished its adjuvant properties by inhibiting OVA-specific IgG production. Therefore, our data indi-
cate that EPS may exert opposing effects on antibody production in vivo to the adjuvant-like effect of
whole lactic bacteria strains, as reported by others. Moreover, this study expands our understanding of
a role of EPS in the “cross-talk” between biofilm forming bacteria and the immune system.
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Introduction
Exopolysaccharides (EPSs), major components of extra-
cellular polymeric substances, are produced by bacteria dur-
ing formation of biofilm [1]. However, in contrast to well-
known receptors of the bacteria cell-wall structures, such as
Toll-like receptor 4 (TLR-4) for lipopolysaccharide (LPS)
of Gram-negative bacteria or TLR-2 for peptydoglycans of
Gram-positive bacteria [2], it is not clear whether EPS can
be recognized by the pathogen recognition receptors (PRRs).
On the other hand, the immunoregulatory potential of EPS
from various bacteria has been demonstrated in a number
of papers [3-6]. Moreover, it is well established that EPS,
a component of biofilm matrix, plays an important role in
bacteria immune evasion and resistance to anti-bacterial
agents, such as antibiotics and antiseptics [7-9].
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It has been shown that EPSs from different Lactobacil-
lus strains not only effectively alter the production of inflam-
matory mediators by the cells of innate immune system but
can also affect antigen-specific humoral response [10, 11].
In our laboratory Lactobacillus rhamnosus KL37C, the
high-level-EPS producer, have been selected out of sever-
al tested lactobacilli for investigations of EPS immunoreg-
ulatory properties. Recently, we have shown that crude EPS
(cEPS) significantly ameliorates arthritis in the active mod-
el of collagen-induced arthritis (CIA) in mice, especially
when LPS was used as adjuvant [11]. Independently, other
reports have shown that oral administration of L. rhamno-
sus attenuates CIA and inhibits arthritogenic autoantibod-
ies [12]. Therefore, it was reasonable to check whether sys-
temic administration of cEPS affects the development of
CIA and depresses the production of anti-collagen IgG.
Indeed, cEPS strongly reduced the serum level of total col-
lagen-specific IgG and of both measured subclasses of IgG,
namely IgG1 and IgG2a [11]. The inhibitory effect of EPS
on the humoral response was also confirmed by others [13].
The main aim of this study was to further evaluate the
immunosuppressive potential of crude EPS derived from
L. rhamnosus KL37C in the OVA-model of antigen-spe-
cific antibody production in CBA mice. The effect of crude
EPS was compared with that of lipopolysaccharide (LPS)
and the selected polysaccharides derived from other sources.
Finally, we compared the effect of crude EPS (extracellu-
lar polymeric substances) with that of purified form of EPS
(EPS37).
Material and methods
Mice
Inbred CBA/J mice (8-12 weeks of age, 18-22 g) were
maintained in the Animal Breeding Unit, Department of
Immunology, Jagiellonian University Medical College, Cra-
cow. All mice were housed in the laboratory room with
water and standard diet ad libitum. The authors were grant-
ed permission by the Local Ethical Committee to use mice
in this study.
EPS isolation
Exopolysaccharides were obtained from L. rhamnosus
KL37C strain isolated from the faeces of the human new-
borns and from Lactobacillus reuteri 133 from the gas-
trointestinal tract of Gαi2-deficient mice which showed
clinical symptoms of colitis [14, 15]. Briefly, bacteria were
stored at –70oC in MRS broth supplemented with 10% glyc-
erol. Bacteria were cultivated in supplemented MRS liquid
broth (Oxoid, UK) under anaerobic conditions at 37oC for
48 h. Cells were harvested by centrifugation at 8000 rpm
(4oC, 30 min) and washed twice with phosphate buffer solu-
tion (PBS). Bacterial mass was suspended in water (10 ml)
and sonicated three times for 5 min, in an ice bath. After
centrifugation at 4000 rpm (30 min, 4oC), the supernatant
was centrifuged twice at 12 000 rpm, 4oC for 1 h and then
precipitated with five volumes of cold ethanol (–20oC,
overnight). The precipitated material was recovered by cen-
trifugation at 12 000 rpm 4oC for 20 min and freeze-dried.
Isolation of EPSs was performed by gel filtration on the
TSK HW-50 column (1.6 × 100 cm) in 0.05 M aqueous
pyridine acetate buffer (pH 5.6). The eluate was monitored
with a Knauer differential refractometer. The first fraction,
eluted in the void volume, contained polysaccharide (crude
EPS) and was the subject of the present investigation.
Purification of EPS37
Purification of crude EPS from L. rhamnosus KL37C
was performed as described before [16]. The freeze-dried
preparation of cEPS was dissolved in buffer (50 mM Tris-
HCl pH 7.5, 10 mM MgCl2) and treated with DNase and
RNase (37oC, 6 h) with protease from Streptomyces griseus
(both Sigma-Aldrich, Germany) (37oC, 16 h), then dialyzed
against water at 4oC for 24 h. The resuspended polysac-
charide was purified by ion-exchange chromatography on
DEAE-Sephadex A-25, 1.6 × 20 cm, column (Pharmacia
Fine Chemicals, Sweden). The pure EPS37 was eluted with
20 mM Tris buffer, pH 8.2. The fractions containing EPS37
were pooled, desalted by dialysis against water at 4oC for
24 h and lyophilized.
Mice immunization with OVA
If not stated otherwise, mice were given intraperi-
toneally injection of OVA (200 mg/mouse) in the presence
of LPS (Escherichia coli 011 : B4; 1 µg/mouse; both Sig-
ma-Aldrich, Germany), or/and with cEPS or EPS37 or EPS
from L. reuteri 133 (cEPS133); 50 µg/mouse twice, on day
0 and 14. Seven days after the second immunization mice
were bled and serum was collected. Level of OVA-specif-
ic antibodies was measured by ELISA.
Measurement of serum OVA-specific antibody titer
The level of antibodies specific to OVA in mouse serum
was measured by ELISA test. Briefly, plates were coated
overnight with OVA (5 µg/ml). Serial dilutions of mouse
serum in PBS were applied to antigen-coated wells for 1 h
at room temperature. Immunoglobulins in tested serum sam-
ples were detected using biotin-conjugated antibodies
against IgG (Sigma-Aldrich, Germany), IgG1 (MP Bio-
medicals, USA), or IgG2a (Southern Biotech, USA). The
amount of antibody was expressed in arbitrary ELISA units
calculated from anti-OVA titer: 1 Unit = 1/100 titers of anti-
bodies specific to OVA.
Statistical analysis
Statistical significance of differences between groups was
analyzed using one-way ANOVA, followed, if significant,
by a Tukey test for post hoc comparison. Results are
expressed as mean ± SEM values. A p-value < 0.05 was con-
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sidered statistically significant. Analysis was performed using
Graphpad Prism v. 5.01 (GraphPad Software, Inc., USA).
Results
Effects of crude EPS on the level of OVA-specific
IgG
To examine the immunosuppressive potential of crude
EPS on humoral response in mice we used the protocol of
OVA-specific antibody production and the effect of cEPS
was compared with that of LPS. In comparison to the pre-
liminary studies we extended our present investigation on
a measurement of IgG subclasses [11]. Lipopolysaccharide,
a well-known bacterial stimulator of B cell proliferation [17]
behaved as a strong adjuvant in all our experiments, enhanc-
ing significantly OVA-specific IgG of all tested subclasses
(10-20-fold enhancement). Crude EPS, in contrast to LPS,
slightly inhibited the serum concentration of OVA-specific
IgG (total IgG, IgG1 and IgG2a), as shown in Fig. 1. We did
not find any effect of cEPS on anti-OVA IgM production in
our experimental set-up (data not shown). On the other hand,
cEPS not only reduced the production of OVA-specific anti-
bodies when injected with OVA alone, but also abolished
the adjuvant effect of LPS. Indeed, when cEPS was given
simultaneously with antigen and LPS, the serum concentra-
tion of anti-OVA IgG was markedly reduced (Fig. 2).
Different routes of EPS injection and the
production of OVA-specific IgG
To exclude the effect of local interactions between crude
EPS and OVA, the antigen and cEPS were administered by
different routes. The results shown in Fig. 3 clearly indicate
that cEPS injected intraperitoneally (i.p.) or intravenously
(i.v.) leads to reduction of the production of anti-OVA IgG.
However, the strongest suppression was observed after intra-
venous administration of cEPS. By contrast, subcutaneous
injection (s.c.) of cEPS only slightly increased the serum
level of OVA-specific IgG. In all experiments OVA was
applied intraperitoneally.
4000
3000
2000
1000
0
Fig. 1. The effect of crude EPS on OVA-specific IgG, IgG1 and
IgG2a production. Mice were immunized intraperitoneally with
200 µg OVA alone, OVA together with LPS (1 µg/mouse) or
OVA with cEPS (50 µg/mouse) on day 0 and 14. The level of
IgG (A), IgG1 (B) and IgG2a (C) specific for OVA were meas-
ured by ELISA 7 days after boost immunization. The results are
expressed in arbitrary units: 1U = 1/100 titer of IgG anti-OVA ±
SEM (n = 10). Results are mean of two independent experiments.
The levels of IgGs are shown in brackets. Statistical significance
between levels of IgG are marked as: **p < 0.01; ***p < 0.001
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Fig. 2. Anti-adjuvant effect of cEPS. Mice were immunized
intraperitoneally with 200 µg OVA alone, OVA together with
LPS (1 µg/mouse) or OVA together with LPS and cEPS
(50 µg/mouse) on day 0 and 14. The level of OVA-specific IgG
was measured by ELISA in individual sera collected 7 days after
boost immunization. The results are expressed in arbitrary units
representing 1U = 1/100 titer of IgG anti-OVA ± SEM (n = 15).
Results represent three independent experiments. Statistical sig-
nificance between levels of IgG are marked as: ***p < 0.001.
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The ability of EPS to inhibit OVA-specific humoral
response is not restricted to cEPS derived from
human L. rhamnosus KL37C
Previously we have shown that the ability of cEPS
from L. rhamnosus KL37C to stimulate the production of
cytokines by macrophages differs from that of EPSs derived
from other Lactobacillus strains [10]. To examine whether
EPS-dependent suppression of humoral response is also
strain-specific we compared the effect of cEPS from
L. rhamnosus KL37C with that of other crude EPS isolat-
ed from mice L. reuteri 133 and human L. rhamnosus GG.
As shown in Fig. 4, the production of total IgG anti-OVA
was markedly inhibited by cEPS133. The similar suppres-
sor effect was achieved when we used EPS from L. rham-
nosus GG (data not shown). Nevertheless, the strongest
reduction of serum OVA-specific IgG was caused by cEPS
from L. rhamnosus KL37C.
Effects of crude and purified EPSs on the OVA-
specific IgG production
Finally, we compared the suppressor potential of puri-
fied EPS (EPS37) with that of the cEPS to examine whether
the polysaccharide, but not the other components of crude
EPS is responsible for the reduction of OVA-specific IgG
production. Administration of EPS37 together with OVA
during the primary and secondary immunization resulted
in the inhibition of antigen-specific humoral response to
a similar extent to that observed after administration of
cEPS. Moreover, EPS37 showed also anti-adjuvant effect
by neutralization of the LPS-dependent enhancement of
serum anti-OVA IgG (Fig. 5). Thus, these data suggest that
the contribution of other components of extracellular poly-
meric substances, such as proteins, nucleic acids, are neg-
ligible in the observed suppression of OVA-specific
humoral response.
Discussion
Lactic acid bacteria, the major probiotic bacteria, show
strain-specific intrinsic immunoregulatory properties as was
reported in a number of papers [18, 19]. Wide spectrum of
lactobacilli immunoregulatory activities includes a modu-
lation of effector and regulatory T cell subsets, interactions
with dendritic-cells, macrophages and B cells, with the
mucosal tissue-associated cells especially [19-23]. Indeed,
it has been demonstrated that the oral administration of
some lactobacilli strains can induce oral tolerance. Name-
ly, total and the antigen-specific IgE production was inhib-
ited in atopic dermatitis model NC/Nga mice [24]. On the
other hand, some lactobacilli strains were used as adjuvants
to enhance the production of IgA in the MALT system [25,
26]. Moreover, lactobacilli have been shown to increase the
immunogenecity of orally administered vaccines (e.g.
rotavirus, cholera vaccines) [27, 28]. Such distinct and even
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Fig. 3. Effects of crude EPS on the level of OVA-specific IgG –
alternative routes of cEPS injection. Mice were immunized with
200 µg OVA alone or OVA together with cEPS (50 µg/mouse)
on day 0 and 14. cEPS was administered intraperitoneally (i.p.),
intravenously (i.v.), subcutaneously (s.c.) or rectally (p.r.). In all
cases OVA was administered intraperitoneally. The level of OVA-
specific IgG in serum from individual mice was measured by
ELISA 7 days after boost immunization. The results are expressed
in arbitrary units representing 1U = 1/100 titer of IgG anti-OVA
± SEM (n = 5). The results show one representative experiment.
*p < 0.05 OVA vs. OVA + cEPS i.v.
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Fig. 4.The ability to inhibit OVA-specific humoral response is not
restricted to cEPS from L. rhamnosusKL37C. Mice were immu-
nized intraperitoneally with 200 µg OVAalone, OVAtogether with
LPS (1 µg/mouse) or OVAwith cEPS (50 µg/mouse) or OVAwith
cEPS133 (50 µg/mouse) on day 0 and 14. The level of IgG spe-
cific for OVA were measured by ELISA 7 days after boost immu-
nization. The results are expressed in arbitrary units representing
1U = 1/100 titer of IgG anti-OVA± SEM (n = 5). The results show
one representative experiment. The levels of IgG are shown in
brackets **p < 0.01 OVAvs. LPS; ##p < 0.01 OVA+ LPS vs. OVA
+ LPS + cEPS
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opposite immunomodulatory effects (enhancement vs. sup-
pression of humoral response) of various lactobacilli may
be explained by an extreme structural diversity of the cell
wall components, especially due to the presence of differ-
ent sugar monomers [29, 30]. Interestingly, it has been doc-
umented that EPSs, the major components of lactobacilli
biofilm matrix, show a significant impact on lactic bacteria
immunoregulatory properties, including enhancement of
the humoral response [3]. Moreover, to our knowledge,
apart from our investigations [11], only a few reports have
described the immunosuppressive effects of bacterial EPSs
[5, 31]. All these data support a common opinion that bio-
logical functions of lactobacilli (EPSs) are not only strain-
specific but the final effect also depends on a route of bac-
teria (EPS) administration, i.e. versus oral administration
[32]. However, detailed mechanism of action of EPSs
remains unclear.
In the present study we examined the suppressor activ-
ity of crude EPS derived from L. rhamnosus KL37C in the
OVA-model of antigen-specific antibody production in CBA
mice. In our basal experimental system mice were injected
intraperitoneally with the antigen (OVA), adjuvant (LPS)
and cEPS. Therefore, in contrast to other experimental mod-
els, restricted to oral administration of both EPS and anti-
gen [33, 34] we could observe the effects of EPS on the sys-
temic immune system. Importantly, we used the same route
of OVA immunization, as the one we used previously for
collagen to induce the CIA. Our present data indicate that
cEPS inhibits the production of OVA-specific IgG in a sim-
ilar way as it suppressed the production of anti-collagen IgG
in the CIA [11]. In both unrelated antigenic systems the
strongest reduction of serum level of antigen-specific anti-
bodies was observed in IgG2a subclasses. It suggests that
a polarization of T helper subsets occurs under the influ-
ence of cEPS. Moreover, the present study confirmed “anti-
adjuvant” properties of cEPS as it was able to neutralize the
LPS-dependent enhancement of OVA-specific IgG pro-
duction.
Nevertheless, it is still not known how cEPS attenuates
the activity of LPS and reduces the serum level of antigen-
specific IgG. We can speculate that at least two independ-
ent mechanisms may be responsible for the cEPS-depen-
dent suppression of OVA-specific IgG production. Firstly,
cEPS may interact directly with LPS reducing its contact
with the antigen presenting cells. Secondly, cEPS may
induce T regulatory cells (e.g. T suppressor cells in the
spleen) and indirectly inhibit LPS-dependent proliferation
of B cells. However, to confirm the above hypothesis we
need stronger experimental data.
Importantly, in the present study we have shown for the
first time that purified EPS37 exerted the same inhibitory
properties as the crude EPS. It is of importance for further
investigations as it would be easier to determinate recep-
tor(s) specific for extracellular polysaccharides, especially
for those which are components of a biofilm matrix, using
a purified EPS.
In conclusion, further studies are necessary to confirm
the hypothesis on the mechanism of cEPS-dependent sup-
pression, to decide whether biofilm components such as
EPS interact with PRRs of the cells of innate immune sys-
tem and whether EPS may be used as immunomodulator
with defined properties. Finally, in our opinion, a major gap
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Fig. 5. Comparison of the effect of crude EPS (A) and purified EPS37 (B) on OVA-specific antibody production. Mice were
immunized intraperitoneally with 200 µg OVA alone, OVA together with LPS (1 µg/mouse) or OVA with cEPS (50 µg/mouse)
or OVA with EPS37 (50 µg/mouse) on day 0 and 14. The level of IgG specific for OVA were measured by ELISA 7 days after
boost immunization. The results are expressed in arbitrary units representing 1U = 1/100 titer of IgG anti-OVA ± SEM (n = 10).
Results represent the mean of two independent experiments. The levels of IgG are shown in brackets. ***p < 0.001 vs. OVA;
#p < 0.05 vs. LPS; ###p < 0.001 vs. LPS; ^^p < 0.01 vs. cEPS; $$p < 0.01 vs. EPS37
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in our knowledge about mechanisms of immunomodula-
tion by probiotics (including biofilm EPS) concerns their
diversity and their fate in vivo. Therefore, in the future,
immunoregulatory functions of bacterial (probiotic) poly-
saccharides of a well-characterized structure should be
examined in vitro and then confirmed in animal experi-
mental models.
This study was supported by the grant from the Nation-
al Science Centre No. K/PBW/000559.
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